Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Department of Pharmaceutical Sciences, School of Pharmacy - Boston, MCPHS University, Boston, MA 02115, USA.
Ther Deliv. 2020 Sep;11(9):591-603. doi: 10.4155/tde-2020-0052. Epub 2020 Sep 15.
MicroRNAs (miRNAs) hold the potential to boost therapeutic efficacy and/or reverse drug resistance associated with traditional cancer chemotherapy. Both miRNA mimics and inhibitors have been explored in cancer therapy. Systemic co-delivery of chemotherapeutics and miRNA therapeutics represents an attractive treatment approach, but safe and efficient delivery systems are greatly needed. The regulatory approval of Onpattro paved the way for lipid-based nanoparticles to deliver RNA therapeutics in different settings, including in combination with chemotherapeutics to treat cancer. In this , we discuss the significance of systemic co-delivery of chemotherapeutics and miRNA therapeutics for cancer therapy and highlight the representative examples of this strategy using lipid-based nanoparticles. We also present outstanding roadblocks to clinical translation and provide the latest perspectives.
微小 RNA（miRNA）具有提高治疗效果和/或逆转与传统癌症化疗相关的药物耐药性的潜力。miRNA 模拟物和抑制剂都已在癌症治疗中进行了探索。化疗药物和 miRNA 治疗药物的系统共递药代表了一种有吸引力的治疗方法，但非常需要安全有效的递药系统。Onpattro 的监管批准为脂质纳米粒在不同环境下递送 RNA 治疗药物铺平了道路，包括与化疗药物联合治疗癌症。在这篇综述中，我们讨论了化疗药物和 miRNA 治疗药物的系统共递药在癌症治疗中的重要性，并强调了使用脂质纳米粒的这种策略的代表性实例。我们还介绍了临床转化的突出障碍，并提供了最新的观点。
